Limited Competition: AIDS Malignancy Consortium (AMC) (UM1 Clinical Trials Required)

The summary for the Limited Competition: AIDS Malignancy Consortium (AMC) (UM1 Clinical Trials Required) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Limited Competition: AIDS Malignancy Consortium (AMC) (UM1 Clinical Trials Required): The purpose of the proposed Funding Opportunity Announcement (FOA) is to continue support for AIDS Malignancy Consortium (AMC). AMC is a major infrastructure intended to stimulate cooperative research efforts in the following areas: 1) Design, development, and evaluation of clinical interventions for the prevention and treatment of HIV-associated malignancies; Development of more effective therapeutics and management strategies for HIV-associated malignancies; Investigation of the biology of HIV malignancies within the context of clinical trials; Management of issues of international importance in HIV associated-malignancies; and Distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource for ongoing or future investigations. The AMC must consist of the following functional units: a Coordination Center, Clinical Trial Sites, Network Laboratories, and a Statistical Center. The AMC team must have at least four scientific disease-oriented Working Groups to study Kaposi Sarcoma, Lymphoma, Human papilloma virus-associated cancers, and non-AIDS-Defining cancers. The Network Laboratories will be responsible for routine clinical trial support activities, pathogenesis-driven correlative studies, and clinical pharmacology and pharmacokinetics studies of anticancer/antiviral interactions. All clinical trials to be conducted by the AMC must be available to subjects of all racial/ethnic groups.
Federal Grant Title: Limited Competition: AIDS Malignancy Consortium (AMC) (UM1 Clinical Trials Required)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-CA-19-056
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.393, 93.394, 93.395, 93.396
CFDA Descriptions: Information not provided
Current Application Deadline: January 10th, 2020
Original Application Deadline: January 10th, 2020
Posted Date: September 11th, 2019
Creation Date: September 11th, 2019
Archive Date: February 15th, 2020
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: September 11th, 2019
Applicants Eligible for this Grant
Public and State controlled institutions of higher education
Additional Information on Eligibility
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. See the funding announcements for eligibility details
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-056.html
Grant Announcement Contact
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
More Grants from the National Institutes of Health
Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines (U01 Clinica...
Understanding Phage Biology to Support the Development of Bacteriophage Therapy (R21 Clini...
Strategies to Improve Health Outcomes and to Reduce Disparities in Rural Populations (R01 ...
Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical T...
Organotypic Culture Models developed from Experimental Animals for Chemical Toxicity Scree...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com